Granules India jumps on getting ANDA approval for Loperamide Hydrochloride and Simethicone Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Granules India is currently trading at Rs. 306.85, up by 4.90 points or 1.62% from its previous closing of Rs. 301.95 on the BSE.
The scrip opened at Rs. 301.80 and has touched a high and low of Rs. 307.65 and Rs. 301.80 respectively. So far 21178 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 314.90 and Rs. 300.05 respectively. The current market cap of the company is Rs. 7549.34 crore.
The promoters holding in the company stood at 41.98%, while Institutions and Non-Institutions held 26.16% and 31.85% respectively.
Granules India has received Abbreviated New Drug Application (ANDA) approval for Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC) from US Food & Drug Administration (USFDA). It is bioequivalent to the reference listed drug product, Imodium Multi-Symptom Relief Tablets, 2 mg/125 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
Loperamide Hydrochloride and Simethicone Tablets are indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Granules now have a total of 52 ANDA approvals from US FDA (50 Final approvals and 2 tentative approvals).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
